Additional benefit of the new drug mentioned in the publication.

Note:*Percentage is based on 124 trials that mentioned any additional benefit of the new drugs irrespective of whether or not data were shown to support the claim.¶The authors show any analysis or argument of the additional benefit.†Three trials addressed both the safety profile and the method of administration, six trials only addressed the safety profile, and one trial only addressed the method of administration.‡One trial addressed both the method of administration and patient's compliance rate, and four trials addressed only the patient's compliance rate.§Four trials addressed both safety profile and patient's compliance and one trial only addressed the safety profile.¥One trial addressed both better method of administration and cost and one trial only addressed cost.